Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Single Nucleotide Variants in the Fc Receptor for IgG Are Associated With COPD Severity and Exacerbations in African American Participants From COPDGene and SPIROMICS
LaFon, David C. , Hu, Kaili , Rocco, Alison, Ortega, V.E., Woodruff, P., Christenson, Stephanie A. , Martinez, F.J., Paine, Richard R. , Meyers, Deborah A. , Putcha, Nirupama , Curtis, J.L., Christenson, Stephanie A , Kaner, Robert J. , Krishnan, Jerry A , Curtis, J.L., Labaki, Wassim W. , Pandey, Janardan P. , Nahm, Moon H. , Chong, Zechen , McDonald, Merry‐Lynn

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3188-A3188

10.1164/ajrccm.2025.211.abstracts.a3188 Get It

Abstract Rationale: We have previously shown reduced total IgG, IgG subclasses, and levels/function of pneumococcal-specific antibodies are associated with increased risk for exacerbations of COPD (ECOPD). The binding of IgG to its receptor, the Fc receptor for IgG (FcγR) on immune cells, has a critical role in determining antibody levels and function. In addition to our research demonstrating that IgG heavy chain gene (IGHG) variants are associated with ECOPD, single nucleotide variants (SNVs) in genes encoding FcγR (FCGR1-3, which encode receptor subtypes FcγRI, FcγRIIa/b/c, and FcγRIIIa/b) may also result in antibody deficiency and increased exacerbation risk. Due to technical challenges in accurately identifying SNVs in FCGR, this region has not been well-characterized. The limited data that exist are from people of European descent, and prior studies have not included African American participants. We therefore sought to investigate the hypothesis that distinct SNVs in genes encoding FcγR are associated with disease severity and history of exacerbations in African American people with COPD. Methods: We developed a novel pipeline to identify SNVs in the coding (CDS) regions of chromosome 1 using short-read whole genome sequence data. The pipeline was benchmarked using paired long-read samples from Genome in a Bottle. SNVs were called within CDS regions and analyzed in a meta-analysis of self-reported African American participants in SPIROMICS and COPDGene (n=3063). Genetic variants were tested for association with COPD severity (GOLD spirometry stage 1-2 vs 3-4) as well as COPD exacerbations, adjusting for age, sex and principal components controlling for population structure. Results: Eight SNVs were significantly associated with frequent ECOPD (≥2 in one year) in the meta-analysis of African American COPDGene and SPIROMICS participants (Table). Seven of these 8 SNVs were found in FCGR3; 4 in the activating FCGR3A subtype, and 3 in FCGR3B. Seven of 11 SNVs associated with COPD severity were in FCGR3 (4 in FCGR3A; 3 in FCGR3B). One SNV (rs371849) was associated with both frequent exacerbations (P=0.002) and COPD severity (P=0.044). Conclusions: We used a cutting-edge variant calling pipeline to identify multiple SNVs in FCGR, primarily involving FcγRIII receptor subtypes, associated with COPD severity and exacerbations in African American participants in SPIROMICS and COPDGene. FcγRIII variants are known to cause impaired antibody levels and function in people of European descent. The structural and functional importance of newly recognized variants in African American cohorts require further study, as they may represent immunogenetic risk factors for antibody deficiency and exacerbations.
Racial and Ethnic Disparities in Pulmonary Rehabilitation Utilization Among COPD Patients With Exacerbations
LOHANA, ABHI , Kumar, B Saravana, Neel, Sejal , Deepak, Vishal , Kumar, B., Chander, Subhash

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3182-A3182

10.1164/ajrccm.2025.211.abstracts.a3182 Get It

Abstract Background: Pulmonary rehabilitation (PR) is a comprehensive intervention and essential component for integrated care with patients with chronic respiratory diseases, especially Chronic Obstructive Pulmonary Disease (COPD). American Thoracic Society (ATS) strongly recommends PR for patients with COPD after exacerbation. PR has been shown to reduce mortality, improve quality of life, and decrease hospital readmissions in patients with COPD. Despite these benefits, access to PR remains unevenly distributed, particularly among racial and ethnic minorities. This study explores racial and ethnic disparities in PR utilization among COPD patients with a history of exacerbations. Methods: Utilizing data from the TrinetX Research Network, we examined two cohorts of COPD patients. Cohort 1 (N=493) consisted of patients with COPD and prior exacerbations who received PR, while Cohort 2 (N=457,573) included similar patients who did not receive PR. Demographics, specifically, race and ethnicity, were statistically analyzed to assess the presence and significance of disparities, using chi-square tests and standardized mean differences (SMD) to provide a comparative framework.Results:493 patients were in the PR group and 457,573 patients in the non-PR group, comprising 458,066 patients across both cohorts. Among the 493 patients in the PR cohort, the largest group was categorized as Other Race (192 patients, 38.9%, p < 0.001, SMD = 1.040), followed by White patients (154 patients, 31.2%, p < 0.001, SMD = 0.899). Black or African American and Asian patients were both minimally represented, with 10 patients each (2.0%, p < 0.001, SMD = 0.319 and SMD = 0.034, respectively), while 137 patients (27.8%, p < 0.001, SMD = 0.349) were of Unknown Race. In contrast, the non-PR cohort, comprising 470,239 patients, had a substantially higher proportion of White patients (330,409 patients, 72.2%) and a significantly greater representation of Black or African American individuals (42,573 patients, 9.3%, p < 0.001, SMD = 0.319) and Hispanic or Latino individuals (13,709 patients, 3.0%, p < 0.001, SMD = 0.249) compared to the PR cohort. Conclusion: This study highlights significant disparities in the utilization of PR among COPD patients, with underrepresented racial and ethnic groups demonstrating lower access to this intervention. These findings highlight the need for targeted strategies to address potential barriers to PR, promoting equitable access across diverse populations. Further investigation into structural and socioeconomic factors influencing PR access will be crucial to fostering inclusive care and reducing healthcare disparities in COPD management.
Healthcare Resource Utilization Associated With Treatment for Refractory Mycobacterium Avium Complex Lung Disease: Comparison of Amikacin Liposome Inhalation Suspension (ALIS) vs Non-ALIS Antibiotic Treatment
Aksamit, Timothy R. , Waweru, Catherine, WELCH, EMILY , Markson, Leona E., Wang, Ping

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3172-A3172

10.1164/ajrccm.2025.211.abstracts.a3172 Get It

Abstract Rationale Amikacin liposome inhalation suspension (ALIS), as part of a combination antibacterial regimen, is currently the only FDA-approved treatment for patients with refractory Mycobacterium avium complex lung disease (rMACLD). MAC is the most common cause of nontuberculous mycobacterial lung disease (NTMLD). A real-world evidence study demonstrated significant decreases in hospitalizations from baseline over a 12-month follow-up period following ALIS initiation; however, study conclusions were limited by the absence of a comparator arm. In this study, we compared healthcare resource utilization in US patients who initiated ALIS versus non-ALIS antibiotic treatment for possible rMACLD. Methods This was a retrospective claims analysis using the Merative™ MarketScan® databases between 2016 and 2021. As no diagnosis codes for MACLD exist in claims, we defined 2 cohorts of patients receiving treatment for possible rMACLD as follows: 1) patients who initiated ≥28 days of continuous treatment with ALIS; and 2) patients who initiated ≥28 days of continuous treatment with ≥1 non-ALIS antibiotic used to treat rMACLD (i.e., parenteral aminoglycoside, clofazimine, fluoroquinolones, linezolid, tedizolid, or bedaquiline) ≥6 months after initiating treatment used for MACLD (i.e., with a combination of ≥2 antibiotics from a macrolide, ethambutol, and a rifamycin). The date of initiating treatment with ALIS or non-ALIS antibiotic for rMACLD was referred to as the index date. Other inclusion criteria: ≥1 diagnosis code for NTMLD anytime pre-index, ≥6 months continuous eligibility pre-index, and ≥12 months continuous eligibility post-index. Hospitalizations (all-cause, respiratory-related, NTMLD-related) and emergency room (ER) visits at 0-6 and 7-12 month post-index periods were compared with baseline (6 month pre-index period) per treatment arm. Results A total of 116 patients comprised the ALIS cohort and 63 patients the non-ALIS cohort. In the ALIS cohort, statistically significant reductions from baseline in all-cause, respiratory-related, and NTMLD-related hospitalizations were observed during the 7-12 month post-index period (Table). In contrast, the non-ALIS cohort did not show significant reductions from baseline in hospitalizations at follow-up. No statistically significant changes from baseline in ER visits were observed in either group. Conclusions Patients treated with ALIS for rMACLD had statistically significant reductions in hospitalizations from baseline during the 7-12 month post-index period, whereas no statistically significant improvements in hospitalizations were observed in the non-ALIS antibiotics group.
Associations Between Recalled Memories of the ICU Stay, Delirium, and Mental Health Outcomes in Critical Illness Survivors at 1-month Follow-up in a Critical Illness Recovery Center
Phan, Emily, Eaton, Tammy L. , Boehm, Leanne M. , Butcher, Brad W. , Danesh, Valerie , McPeake, Joanne , Lindroth, Heidi , Girard, T.D., Potter, Kelly

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3144-A3144

10.1164/ajrccm.2025.211.abstracts.a3144 Get It

Abstract Rationale: Critical illness survivors often experience anxiety, depression, and post-traumatic stress disorder (PTSD) due to traumatic experiences, sedation, and delirium. Early interventions of psychological support may help mitigate mental health deficits post-ICU. Memory of the ICU stay may play a key role in addressing trauma and facilitating therapeutic engagement. Therefore, we sought to determine the relationship between ICU memory recollection, in-ICU delirium, and mental health outcomes at 1-month follow-up in a critical illness recovery center. Methods: We analyzed data collected at 1-month follow-up in a critical illness recovery center seeing adults who had ICU stays of >4 days with sepsis, respiratory failure, and/or delirium. Patients were asked, “Do you remember your experience in the ICU, and if so, can you describe your most impactful memories?” and we qualitatively coded responses for A) presence/absence of memories and B) type of memories described. We analyzed unadjusted associations between demographic, clinical, and mental health measures (anxiety, depression, and PTSD) and memory recollection using chi-square and Wilcoxon rank-sum tests. Results: Among 196 patients seen at 1-month follow-up, 96 (49%) reported memories of their ICU stay. Of these, 44 (46%) described support they received in the ICU (e.g., feeling “safe and watched” by ICU staff, spouse at bedside), 36 (38%) recalled delusions and/or hallucinations (e.g., being kidnapped), 35 (37%) remembered specific treatments (e.g., cardioversion), and 33 (34%) described symptoms (e.g., pain, constipation). Baseline characteristics and critical illness features are shown in the Table. Patients who reported no memories of their ICU stay were more frequently admitted with neurological diagnoses, whereas those who reported memories were more often admitted with trauma or burns (p<0.001). Those without memories had more delirium days than those reporting memories (p=0.02). Although PTSD and anxiety symptoms at 1-month follow-up were not associated with memories, patients who remembered their ICU stay had fewer depression symptoms (p=0.04). Conclusions: One month after their critical illness, half of survivors recalled their ICU experience, with memories ranging from supportive interactions to distressing experiences. In unadjusted analyses, memory recollection was associated with fewer depressive symptoms during follow-up, but a larger study is needed to determine whether this association persists after adjusting for potential confounders. Memories of the ICU may provide a therapeutic foundation for interventions targeting depression after critical illness, such as exposure therapy or ICU diaries, which may improve mental health outcomes in critical illness survivors.
The Impact of Reconnecting With Survivors After Critical Illness on Clinical Practice and Job Satisfaction in Nursing: A Mixed-Methods Survey
Eaton, Tammy L. , Boehm, Leanne M. , Lagina, Madeline , Valley, Thomas S. , Danesh, Valerie , McPeake, Joanne , Potter, Kelly , Lindroth, Heidi , Taylor, Stephanie Parks

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3143-A3143

10.1164/ajrccm.2025.211.abstracts.a3143 Get It

Abstract Rationale: ICU nurses can experience high levels of burnout and job dissatisfaction due to stressors associated with high-stakes patient care, uncertain outcomes, and constant exposure to death. Witnessing patient recovery and/or disability status in the weeks or months after hospital discharge through reconnection with survivors of critical illness and their families may offer emotional and professional benefits to ICU nurses. However, the impact of connecting with patients’ post-ICU outcomes on nursing clinical practice and job satisfaction has not been well explored. This study aimed to investigate pragmatic perspectives from ICU nurses related to their insights on long-term patient outcomes after critical illness with a goal of identifying key mechanisms that may be associated with impacts on clinical practice and job satisfaction. Methods: A web-based investigator-designed survey was distributed to ICU nurses with endorsement from the American Association of Critical-Care Nurses for completion via their website and annual conference. Survey items included quantitative and open-ended prompts to examine the impact of reconnecting with ICU survivors on clinical practice and job satisfaction. Thematic analysis was performed on free-text responses. Results: Fifty-four ICU nurses (76% female) participated in the survey (June 2023-May 2024), with a median age of 41 years and a median of 7 years of critical care experience. Among them, 89% reported that reconnecting with survivors positively impacted their job satisfaction, and 78% felt that reconnecting influenced their clinical practice. Thematic analysis revealed three themes: Empathy and Human Connection – Nurses felt validated and fulfilled knowing their care positively impacted patients’ lives, reinforcing the meaning of their work. These interactions fostered greater empathy, reminding nurses of the real-life impact of their care.Validation of Effort and Accomplishment – Nurses reported a stronger sense of accomplishment seeing the positive outcomes of their work. Reconnecting with survivors reaffirmed the importance of their roles, strengthening nurses’ sense of purpose and commitment.Positive Emotional Impact and Job Satisfaction – Interactions with survivors provided emotional uplift, enhancing job satisfaction and reminding nurses of the rewarding aspects of their roles. Gratitude and progress from survivors motivated nurses, helping them manage the emotional challenges of ICU work. Conclusion: Reconnecting with ICU survivors and their families may have positive impacts on job satisfaction and clinical practice by providing emotional rewards, reinforcing nurses’ professional purpose, and validating their contributions to patient recovery. Embedding structured, low-cost re-engagement activities with critical illness survivors could offer valuable benefits to the ICU nurse workforce.
Self-management of Sedative Therapy Among Mechanically Ventilated Intensive Care Unit Patients: A Two-group Randomized Clinical Trial
Tracy, Mary Fran , Wittwer, Erica D. , Mandrekar, Jay , Harmsen, William S. , Peterson, P.E., Weinert, Craig , Chlan, Linda L. , Gajic, Ognjen , Lal, Amos , Peterson, P.E.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3140-A3140

10.1164/ajrccm.2025.211.abstracts.a3140 Get It

Abstract RATIONALE: Clinical practice guidelines recommend that mechanically ventilated patients (MVPs) receiving sedative therapy achieve a target goal of ‘awake and calm’ when medically possible. However, ICU sedation practices rely on clinicians’ administration of medications based on observations of patients’ arousal/motor activity that are not consistently based on symptom assessments nor consider patients’ preferences. We hypothesized that MVPs would safely self-manage sedative therapy (SMST) base on individual needs and perceived anxiety while experiencing less sedative exposure and delirium. METHODS: A two-group randomized clinical trial conducted in two Midwestern academic medical centers enrolled 161 MVPs willing and able to depress a medication delivery push-button device who remained on protocol for 7 days or until extubated, withdrew or died. Control group (CG) patients (n=81) received sedative medications administered by ICU nurses per unit protocols. Experimental SMST group patients (n=80) received a basal infusion of dexmedetomidine (0.2 mcg/kg/hr titrated per algorithm) + self-administered bolus doses (0.25 mcg/kg up to 3/hour). Primary outcomes were anxiety ratings using a 100-mm visual analog scale (VAS-A), sedation intensity score (aggregate summary of 9 intravenous sedative/opioid medications received range 0-36), and incidence of delirium using the CAM-ICU. Analyses were descriptive and parametric statistics and Generalized Estimating Equations. RESULTS: Patients were predominantly White (93%) females (55%), mean age 58.9+15.1 years receiving mechanical ventilation for respiratory failure (60%) with mean APACHE III of 84.5 + 32.5. Anxiety was highly variable over time wherein patients in both groups endorsed the full range from 0-100. VAS-A over time between groups was -0.06 (p=0.98) indicating that anxiety was 0.06 units lower for SMST patients versus CG. Median sedation intensity in SMST group 11.8 + 9.6, compared to CG 12.7 + 9.6 (p = 0.55) over 7 days. 10.2% of SMST patients had one or more incident delirium events compared to 8.5% of CG (p =.97). Hypotension was experienced equally between groups: 22 in SMST, 23 in CG (p = 1.0) as were device disruptions: 2 in SMST versus 3 in CG (p = 1.0). 82% of SMST were satisfied/very satisfied with ability to self-administer dexmedetomidine; 70% were satisfied/very satisfied with ability to control anxiety; 68% were satisfied/very satisfied with the level of relaxation experienced. CONCLUSIONS: Although there were no significant differences between groups on the primary outcomes, the experimental SMST intervention was safe with high patient-reported satisfaction. SMST may be a viable new paradigm for sedative therapy administration among select ICU patients.
Results From Airflow-3: Randomized, Double Blind, Sham Controlled Study of Targeted Lung Denervation in Patients With COPD
Criner, G.J., Sue, Richard, Ghattas, Christian , Guibert, Nicolas , Valipour, A., Cardenas, José De , Soto, Jose Soto , Slebos, Dirk‐Jan , Bhatt, Surya P. , Strange, Charlie , Degano, Bruno , Eisenmann, Stephan , Marquette, Charles‐Hugo , Sciurba, Frank C. , Shah, Pallav L.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3112-A3112

10.1164/ajrccm.2025.211.abstracts.a3112 Get It

Abstract Rationale: The D'Nerva Targeted Lung Denervation (TLD) System uses radiofrequency energy delivered bronchoscopically to the main bronchi to disrupt parasympathetic nerve innervation to the lung. AIRFLOW-3 clinical trial was a randomized, double blind, sham controlled study to determine the impact of TLD on COPD exacerbations. Methods: AIRFLOW-3 patients had symptomatic COPD (CAT ≥10) with moderate to very severe airflow obstruction (GOLD stage II-IV: 25% ≤ FEV1 ≤ 80% predicted, FEV1/FVC<0.70) and GOLD E status (≥2 moderate or ≥1 severe exacerbation in the prior 12 months) despite optimal medical therapy. The primary endpoint was a time-to-first event comparison of the probability of subjects having a moderate or severe exacerbation, between the Treatment arm (TLD + optimal medical therapy) and the Sham Control arm (optimal medical therapy). Results: 388 patients were randomized 1:1 at 32 clinical sites across the US, EU, and UK. Patients were 67.8 (SD 7.1) years of age, ex-smokers with a 46.7 (22.0) pack-year smoking history, and 41.0 (11.8) post bronchodilator FEV1% pred. SGRQ-C and CAT scores were 62.5 (17.0) and 23.6 (6.3), respectively. Over 90% of patients were on triple therapy (LAMA+LABA+ICS) at baseline and through 1 year of follow up. 42% of patients had prior-year COPD hospitalization(s). There was no difference between groups in the analysis of the primary endpoint. At 1 year, the sham arm exhibited a statistical decline in lung function (decrease in FEV1 and FVC) and worsening of gas trapping (increase in RV). Lung function and gas trapping were stable in the treatment arm. The treatment arm exhibited a statistically significant improvement in dyspnea at one year compared to sham (mMRC, and TDI). These observations led to the identification of a subgroup of TLD treatment responders corresponding to an airway predominant phenotype (lung hyperinflation in the absence of significant emphysema) that demonstrated clinically and statistically significant improvements in lung function and exacerbation frequency and severity (Table). Conclusions: The AIRFLOW-3 clinical trial failed to meet its prespecified primary endpoint. Post-hoc analysis of this robust dataset led to the identification of a responder profile that achieved significant and sustained improvements in lung function, and exacerbation reduction. A future clinical study is being designed to confirm these findings.
Class C GPRC5A in Human Airway Smooth Muscle
Thompson, Martin W., Venkatachalem, S., Prakash, Y.S., Hamrick, Samantha K. , Thompson, M., Drake, Li Y. , Venkatachalem, S., Pabelick, Christina M. , Prakash, Y. S.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3084-A3084

10.1164/ajrccm.2025.211.abstracts.a3084 Get It

Abstract Rationale: Asthma involves airway inflammation, hyperresponsiveness (AHR), and remodeling (cell proliferation and fibrosis), with both aspects not fully alleviated by current therapies. GPCR-based drugs represent a major aspect of current asthma therapy. Asthmatic airways express several orphan receptors with unknown physiological roles, highlighting a potentially novel and significant area for therapeutic exploration. Herein, we focus on orphan retinoic acid (RA)-induced Class C GPCR members GPRC5A (RAIG1; 5A) and GPRC5B (RAIG2; 5B). We leveraged recently identified 5A agonists to test the hypothesis that these GPCRs have alleviating effects in airways. Methods: Primary human airway smooth muscle cells (ASM) originating from non-asthmatic (NA) and asthmatic (Asth) individuals were obtained post-surgery from lung tissues after approval by the Mayo Clinic Institutional Review Board. PRESTO-Tango assay was used to determine 5A and 5B activity. cADDis assay was used to assess cAMP levels. Fluorescence imaging was used to determine calcium regulation. Recently identified 5A agonists [tryptamine, 7 fluoro-tryptamine (7FT), L-tryptophan, N-methyltryptamine, and indole-3-acetic acid] were used in assays, along with RA and 5A vs. 5B siRNAs. Results: PRESTO-Tango assay showed that tryptamine (10/100 µM) and 7FT (1/10/100 µM) increased 5A activity while high concentrations of 7FT (100 µM) increased 5B activity as well. cADDis assay showed 100 µM tryptamine increased cAMP more than 1/10 µM tryptamine and that 10 µM 7FT increased cAMP more than 1/100 µM 7FT in NA ASM.Calcium imaging showed that 5A agonist blunts responses to histamine, especially in Asth ASM. Calcium responses were higher in Asth ASM and 5A siRNA-treated ASM while 5B siRNA had an alleviating effect. Conclusions: Class C GPCRs 5A and 5B interestingly have opposing effects in human ASM towards blunting calcium responses to bronchoconstrictor agonists in the context of asthma. Thus, 5A agonists and 5B antagonists may represent novel GPCR-based approaches in airway diseases.
Hydrogen Sulfide (H2S) Alleviates Hyperoxia-induced Changes in Intracellular Calcium Regulation in Human Fetal Airway Smooth Muscle
Borkar, N.A., Prakash, Y.S., Thompson, Michael D. , Bartman, Colleen M. , Hamrick, Samantha K. , Prakash, Y. S. , Pabelick, Christina M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3083-A3083

10.1164/ajrccm.2025.211.abstracts.a3083 Get It

Abstract Rationale: Moderate hyperoxia (<60% O2) in premature infants promotes bronchial airway hyperresponsiveness (AHR) and impaired bronchodilation involving airway smooth muscle (ASM). Understanding mechanisms by which hyperoxia initiates long-term bronchial airway changes in prematurity is critical for novel therapies for wheezing disorders and asthma in children. Underdeveloped lungs in prematurity have immature antioxidant systems, which may be due to disrupted dynamics that promote susceptibility to oxidative stress from O2. Cytoplasmic and mitochondrial calcium signaling mechanisms and O2 metabolism are pathways highly relevant to ASM and airway disease. We propose that the novel gasotransmitter hydrogen sulfide (H2S) attenuates effects of O2 in developing ASM and hypothesize that hyperoxia in prematurity promotes cellular and mitochondrial calcium signaling dysfunction, effects which are counteracted by H2S.Methods: Human fetal (fASM) cells isolated from tracheobronchial samples of de-identified 18-22 week fetuses following fetal demise (Mayo IRB approved as exempt) were exposed to 21% vs 40% O2. fASM were treated 24-72 hours with H2S donor GYY4137, mitochondrial-specific H2S donor AP39, cystathione-β-synthase (CBS) stabilizer AdoMet, cAMP inhibitors SQ22536 or KT5720, or vehicle control (DMSO). CBS shRNA lentiviral particles were used to generate stable knockdown cell lines. Protein markers were measured by Western blot. Intracellular calcium ([Ca2+]i) was measured using 5μM Fura-2/AM and mitochondrial calcium ([Ca2+]m) with 1μM Rhod-2 AM using fluorescence microscopy. Results: CBS expression was lower in fASM exposed to 40% O2 compared to 21% O2. Lentivirus induced CBS KD was exacerbated by 40% O2. Hyperoxia increased [Ca2+]i and [Ca2+]m response to histamine (10μM) in vehicle and Scr controls compared to normoxia. CBS KD increased [Ca2+]i and [Ca2+]m responses to histamine compared to Scr fASM in 21% O2. CBS KD fASM exposed to hyperoxia showed increased [Ca2+]i and [Ca2+]m responses to histamine, but the effect was not amplified by CBS KD. [Ca2+]i and [Ca2+]m responses to histamine were decreased in normoxia by H2S donors GYY4137 (50μM) and AP39 (100nM) and CBS stabilizer AdoMet (100nM); effects which also blunted hyperoxia induced increases. SQ22536 and KT5720 inhibited effects of AP39 and GYY4137 in hyperoxia. Conclusions:Our findings suggest hyperoxia leads to [Ca2+]i and [Ca2+]m dysfunction in developing airway cells, which can be alleviated through modulation of H2S pathways, offering potential targets for future therapies to blunt hyperoxia effects on bronchoconstriction and bronchodilation. Acknowledgment: Supported by AHA Postdoctoral Fellowship 20POST35210002 (Bartman), NIH R01 HL-056470 (Prakash), and HL-160570 (Pabelick).
Novel Synthesized KpSAT Peptides Regulates Airway Smooth Muscle Remodeling
Ramakrishnan, Y. , Tesch, J., Balraj, Premanand , Kumar, A. , Seetharaman, J. , Ambhore, Nilesh Sudhakar , Pabelick, Christina M. , Prakash, Y. S. , Sathish, Venkatachalem

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3082-A3082

10.1164/ajrccm.2025.211.abstracts.a3082 Get It

Abstract Background: Kisspeptins (Kp) are a group of hypothalamic peptides that aid in regulating pubertal development and sex hormone signaling. In our recent studies, we observed the important role of Kp-10 (Kp peptide) and its receptor KISS1R signaling in regulating the airway smooth muscle (ASM) structure and function. In these studies, we observed significantly reduced expression of KISS1R during asthma pathophysiology suggesting a loss of protective mechanism and exogeneous Kp-10 may be protective in the context of asthma. Studies have shown that specific modifications to the amino acids of Kp peptides can result in increased binding efficiency and receptor activation. Accordingly, we developed three novel Kp peptides, named KpSATs (13A, 13B, and 13C), and tested the potential effects/efficiency on ASM cell remodeling. Methods: The Molecular docking of the KpSAT peptides (13A, 13B and 13C) with the receptor KISS1R were performed using HPEPDOCK. KpSATs were synthesized by GenScript (New Jersey, US) with purity of ≥97%. Primary human ASM cells isolated from surgical lung resections (Mayo Clinic IRB-approved) were cultured in DMEM-F12. Cells were treated with PDGF (2ng/mL) and/or TGF-β (2ng/mL) with/without treatments of KpSATs (13A, 13B, and 13C: 250nM-1µM) and Kp-10 (1µM). ASM cell proliferation was measured using MTT. Extracellular matrix (ECM) deposition (fibronectin and collagen-I/III) studies were performed using In-Cell Western (LiCor-odyssey). The mechanistic signaling pathway (phospho-PKC-δ) were measured using Western blot analysis. Results: In the novel KpSATs, we substituted three amino acids in the endogenous Kp-13 sequence, Y10W and P12T for KpSAT-13A; S6A and P12T for KpSAT-13B; and S6A and Y10W for KpSAT-13C. The peptides dock in the orthosteric ligand binding pocket attained with docking scores ranging from -250 to -280. The MTT assay indicated a reduction in PDGF-induced ASM cell proliferation upon exposure to KpSATs. Notably, we found that KpSAT-13A and KpSAT-13B had significant effects in reducing proliferation at lower concentrations of 500nM compared to 1µM of Kp-10. Furthermore, ECM deposition studies showed a significant reduction of TGF-β1-induced collagen-I/III and fibronectin in ASM cells exposed to KpSAT-13A and 13B. In addition, we observed significant inhibition of PDGF-induced phospho-PKC-δ by KpSAT-13A and 13B. Conclusion: Overall, these findings highlight that modification in amino acid sequence in endogenous Kp-13 sequence significantly increases the potency of synthesized novel KpSATs on ASM cells. In addition, KpSATs showed better inhibitory effects with a lower concentration compared to Kp-10 and could be considered as a promising therapeutic strategy to mitigate asthma.